{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:13:53Z","timestamp":1791346433757,"version":"4.3.1"},"reference-count":27,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2011,9,21]],"date-time":"2011-09-21T00:00:00Z","timestamp":1316563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Study Type \u2013 Therapy (case control)<\/jats:p>\n                    <jats:p>Level of Evidence\u20033b<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What's known on the subject? and What does the study add?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>Angiotensin II is the main effector peptide in the bladder local renin\u2010angiotensin system. This experiment demonstrates the role of this local renin\u2010angiotensin system with respect to bladder outlet obstruction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>To determine if treatment with an angiotensin II type 1 (AT\u20101) receptor antagonist, losartan, can prevent the structural and functional changes that occur in a mouse model of bladder outlet obstruction (BOO).<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Twenty\u2010four Balb\/CAN mice underwent partial urethral obstruction for 6 weeks.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Twelve mice were given oral losartan (10\u2003mg\/kg\/day), and 12 were not. Six mice served as unobstructed controls, and six unobstructed mice were given oral losartan (10\u2003mg\/kg\/day) to determine the effect of angiotensin II inhibition on the normal bladder.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Bladder capacity (C), detrusor pressure during voiding (Pdet) and volume at first non\u2010voiding contraction (NVC1) as a percentage of C were recorded after 6 weeks.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Bladders were stained with haematoxylin and eosin for measurement of detrusor muscular thickness, and graded as 1 = atrophy (&lt;100\u2003\u00b5m thick), 2 = normal (100\u2013200\u2003\u00b5m thick), 3 = hypertrophy (&gt;200\u2003\u00b5m thick) compared with controls.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>\n                            Compared with controls, BOO mice had greater C (153.5 \u00b1 20.9 vs 57.5 \u00b1 7.4\u2003\u00b5l,\n                            <jats:italic>P<\/jats:italic>\n                            &lt; 0.01), higher Pdet (28.8 \u00b1 2.1 vs 12.1 \u00b1 2.1\u2003mm Hg), lower NVC1 (median = 24% vs 54%\n                            <jats:italic>P<\/jats:italic>\n                            = 0.03). BOO mice manifested greater bladder weight (93.2 \u00b1 11.7\u2003mg vs 26.8 \u00b1 2.40\u2003mg,\n                            <jats:italic>P<\/jats:italic>\n                            &lt; 0.01) and greater detrusor muscle thickness (median 3 vs 2,\n                            <jats:italic>P<\/jats:italic>\n                            = 0.02).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Compared with untreated BOO mice, mice treated with losartan had greater mean C (248.8 \u00b1 28.6 vs 153.5 \u00b1 20.9\u2003\u00b5L,\n                            <jats:italic>P<\/jats:italic>\n                            = 0.01), no significant change in mean Pdet (24.7 \u00b1 1.6 vs 28.8 \u00b1 2.1\u2003mm Hg,\n                            <jats:italic>P<\/jats:italic>\n                            = 0.2) and a higher mean NVC1 (47% vs 24%,\n                            <jats:italic>P<\/jats:italic>\n                            = 0.02).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Treatment with losartan mediated an insignificant reduction in mean bladder weight (68.1 \u00b1 9.1\u2003mg vs 93.2 \u00b1 11.7\u2003mg,\n                            <jats:italic>P<\/jats:italic>\n                            = 0.10), but a significant reduction in detrusor muscle thickness (median 2 vs 3,\n                            <jats:italic>P<\/jats:italic>\n                            = 0.02). Losartan did not mediate any significant structural or functional changes in the unobstructed mouse bladder.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>In a mouse model of BOO, treatment with an AT\u20101 antagonist partially prevented the urodynamic and structural changes that otherwise occur with BOO.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2011.10580.x","type":"journal-article","created":{"date-parts":[[2011,9,24]],"date-time":"2011-09-24T20:02:20Z","timestamp":1316894540000},"page":"1841-1846","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Angiotensin II type 1 (AT\u20101) receptor inhibition partially prevents the urodynamic and detrusor changes associated with bladder outlet obstruction: a mouse model"],"prefix":"10.1111","volume":"109","author":[{"given":"Craig","family":"Comiter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardeep S.","family":"Phull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,9,21]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.02.018"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20807"},{"key":"e_1_2_7_4_2","first-page":"1","volume-title":"The Renin\u2010Angiotensin System","author":"Dzau VJ","year":"1993"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00266-5"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)64397-0"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365590801905984"},{"key":"e_1_2_7_8_2","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0022-5347(17)35685-9","article-title":"Angiotensin II receptors in the rat urinary bladder smooth muscle: type 1 subtype receptors mediate contractile responses","volume":"150","author":"Tanabe N","year":"1993","journal-title":"J Urol"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00287.2006"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-1079"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08324.x"},{"key":"e_1_2_7_12_2","first-page":"115","article-title":"Solifenacin succinate prevents urodynamic and detrusor changes associated with bladder outlet obstruction \u2013 a mouse model","volume":"28","author":"Mazar C","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20820"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900261"},{"key":"e_1_2_7_15_2","first-page":"8","article-title":"The role of angiotensin II in stress urinary incontinence: a rat model","volume":"26","author":"Phull H","year":"2006","journal-title":"Neurourol Urodynam."},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000060848.61864.e1"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.03.015"},{"key":"e_1_2_7_18_2","first-page":"R1186","article-title":"Angiotensin II and bladder obstruction in the rat: influence on hypertrophic growth and contractility","volume":"271","author":"Persson K","year":"1996","journal-title":"Am J Physiol"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20029"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2000.00611.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.2000.279.4.C1155"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2003.12.002"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1998.275.5.C1247"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.73.3.413"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2006.12.048"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000283052"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2010.11.018"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.4103\/0971-9261.16070"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2011.10580.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2011.10580.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:41:42Z","timestamp":1761759702000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2011.10580.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,21]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1111\/j.1464-410X.2011.10580.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2011.10580.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,21]]},"assertion":[{"value":"2011-09-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}